{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:32:20Z","timestamp":1790688740125,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00055","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T15:20:13Z","timestamp":1581693613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib"],"prefix":"10.3389","volume":"11","author":[{"given":"Christin","family":"Riess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kehnscherper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Irmscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Shokraie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Friedrich","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Wirthgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Domanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Zimpfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Str\u00fcder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Maletzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","article-title":"Targeting the indoleamine 2,3-dioxygenase pathway in cancer","volume":"3","author":"Moon","year":"2015","journal-title":"J Immunother Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jneuroim.2010.04.003","article-title":"Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions","volume":"225","author":"Avril","year":"2010","journal-title":"J Neuroimmunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3171\/2015.5.JNS141901","article-title":"Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model","volume":"124","author":"Hanihara","year":"2016","journal-title":"J Neurosurg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1178646917691938","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int J Tryptophan Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","article-title":"Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments","volume":"52","author":"Solomon","year":"2018","journal-title":"Semin Cancer Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1756284818815334","DOI":"10.1177\/1756284818815334","article-title":"Role of indoleamine 2,3-dioxygenase in pathology of the gastrointestinal tract","volume":"11","author":"Acovic","year":"2018","journal-title":"Therap Adv Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.21873\/anticanres.11551","article-title":"The kynurenine pathway: a primary resistance mechanism in patients with glioblastoma","volume":"37","author":"Sordillo","year":"2017","journal-title":"Anticancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.imlet.2007.06.001","article-title":"Tumor immune escape mediated by indoleamine 2,3-dioxygenase","volume":"111","author":"Zamanakou","year":"2007","journal-title":"Immunol Lett."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3748\/wjg.v24.i20.2181","article-title":"Indoleamine-2,3-dioxygenase 1\/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer","volume":"24","author":"Ma","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1074\/jbc.M807328200","article-title":"Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells","volume":"284","author":"Jeong","year":"2009","journal-title":"J Biol Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3389\/fimmu.2014.00673","article-title":"Cancer immunotherapy by targeting IDO1\/TDO and their downstream effectors","volume":"5","author":"Platten","year":"2014","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fonc.2018.00370","article-title":"Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer","volume":"8","author":"Fox","year":"2018","journal-title":"Front Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00280-010-1470-2","article-title":"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer","volume":"68","author":"Kanai","year":"2011","journal-title":"Cancer Chemother Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4938285","DOI":"10.1155\/2019\/4938285","article-title":"Targeting immune-related molecules in cancer therapy: a comprehensive in vitro analysis on patient-derived tumor models","volume":"2019","author":"Maletzki","year":"2019","journal-title":"Biomed Res Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e957994","DOI":"10.4161\/21624011.2014.957994","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"3","author":"Vacchelli","year":"2014","journal-title":"Oncoimmunology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"75407","DOI":"10.18632\/oncotarget.12249","article-title":"Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment","volume":"7","author":"Schafer","year":"2016","journal-title":"Oncotarget."},{"key":"B27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40259-018-0291-4","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibition as a strategy to augment cancer immunotherapy","volume":"32","author":"Yentz","year":"2018","journal-title":"BioDrugs."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e112945","DOI":"10.1371\/journal.pone.0112945","article-title":"Involvement of the kynurenine pathway in human glioma pathophysiology","volume":"9","author":"Adams","year":"2014","journal-title":"PLoS ONE."},{"key":"B30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fimmu.2014.00485","article-title":"Tryptophan-catabolizing enzymes\u2014party of three","volume":"5","author":"Ball","year":"2014","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1021\/acsmedchemlett.6b00458","article-title":"Targeting the inhibition of tryptophan 2,3-dioxygenase (TDO-2) for cancer treatment","volume":"8","author":"Abdel-Magid","year":"2017","journal-title":"ACS Med Chem Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"122204","DOI":"10.1172\/jci.insight.122204","article-title":"Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma","volume":"3","author":"Jamieson","year":"2018","journal-title":"JCI Insight."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.18632\/oncotarget.2039","article-title":"Host defense peptides for treatment of colorectal carcinoma-a comparative in vitro and in vivo analysis","volume":"5","author":"Maletzki","year":"2014","journal-title":"Oncotarget."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.4155\/bio-2016-0111","article-title":"LC-MS\/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid, and brain","volume":"8","author":"Fuertig","year":"2016","journal-title":"Bioanalysis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.soc.2015.03.002","article-title":"Molecular biology and immunology of head & neck cancer","volume":"24","author":"Guo","year":"2015","journal-title":"Surg Oncol Clin N Am."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1486353","DOI":"10.1080\/2162402X.2018.1486353","article-title":"Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation","volume":"7","author":"Adam","year":"2018","journal-title":"Oncoimmunology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-12-0014","article-title":"IDO is a nodal pathogenic driver of lung cancer and metastasis development","volume":"2","author":"Smith","year":"2012","journal-title":"Cancer Discov."},{"key":"B40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.21037\/tcr.2018.05.09","article-title":"Matrix metalloproteinase (MMP) and immunosuppressive biomarker profiles of seven head and neck squamous cell carcinoma (HNSCC) cell lines","volume":"7","author":"Bates","year":"2018","journal-title":"Transl Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3109\/00016489.2016.1152631","article-title":"The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma","volume":"136","author":"Seppala","year":"2016","journal-title":"Acta Otolaryngol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.bbrc.2017.03.120","article-title":"Disturbed tryptophan metabolism correlating to progression and metastasis of esophageal squamous cell carcinoma","volume":"486","author":"Cheng","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1179\/135100000101535357","article-title":"IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress","volume":"5","author":"Grant","year":"2000","journal-title":"Redox Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.radonc.2017.08.001","article-title":"Antitumor activity of the dual PI3K\/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer","volume":"124","author":"Tonlaar","year":"2017","journal-title":"Radiother Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3171\/2008.10.JNS081141","article-title":"Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation","volume":"111","author":"Miyazaki","year":"2009","journal-title":"J Neurosurg."},{"key":"B46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1128\/CVI.05402-11","article-title":"Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis","volume":"19","author":"Suzuki","year":"2012","journal-title":"Clin Vaccine Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/glia.20090","article-title":"Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons","volume":"49","author":"Guillemin","year":"2005","journal-title":"Glia."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-12-0549","article-title":"The kynurenine pathway in brain tumor pathogenesis","volume":"72","author":"Adams","year":"2012","journal-title":"Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.jcbfm.9600199","article-title":"In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors","volume":"26","author":"Juhasz","year":"2006","journal-title":"J Cereb Blood Flow Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"107844","DOI":"10.18632\/oncotarget.22253","article-title":"Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget."},{"key":"B51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin Immunopathol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol Cancer Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e172315","DOI":"10.1371\/journal.pone.0172315","article-title":"A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.jocn.2015.06.018","article-title":"The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy","volume":"22","author":"Zhai","year":"2015","journal-title":"J Clin Neurosci."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T15:20:16Z","timestamp":1581693616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2020.00055"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00055","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"article-number":"55"}}